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ABSTRACT 
Innate and adaptive immunity are connected via antigen processing and presentation (APP), which 
results in the presentation of antigenic peptides to T cells in the complex with the major 
histocompatibility (MHC) determinants. MHC class II (MHC II) determinants present antigens to 
CD 4+ T cells, which are the main regulators of the immune response. Their genes are transcribed 
from compact promoters that form first the MHC II enhanceosome, which contains DNA-bound 
activators and then the MHC II transcriptosome with the addition of the class II transactivator 
(CIITA). CIITA is the master regulator of MHC II transcription. It is expressed constitutively in 
dendritic cells (DC) and mature B cells and is inducible in most other cell types. Three isoforms of 
CIITA exist, depending on cell type and inducing signals. CIITA is regulated at the levels of 
transcription and post-translational modifications, which are still not very clear. Inappropriate 
immune responses are found in several diseases, which include cancer and autoimmunity. Since 
CIITA regulates the expression of MHC II genes, it is involved directly in the regulation of the 
immune response. The knowledge of CIITA will facilitate the manipulation of the immune 
response and might contribute to the treatment of these diseases.     
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INNATE AND ADAPTIVE IMMUNITY  
 
The immune system is composed of innate and adaptive branches, which are 
nonspecific and specific, i.e. they target common and unique parts of non-self 
antigens, respectively (Table 1). They discriminate between self and non-self, and 
activate appropriate effectors. Although innate and adaptive immunity appear 
independent, appropriate interactions between them are indispensable for the 
normal function of the immune response. Indeed, “mistakes” that happen in either 
branch can affect the organism as a whole. 
 
Innate immunity is the first defense against invading pathogens and performs the 
function of immune surveillance (Calandra et al., 2003; Janeway, 2001). Cells that 
constitute innate immunity are antigen-presenting cells (APC), including DC, 
macrophages and B cells. Innate immunity does not develop any antigen 
specificity because the discrimination between self and non-self is primarily based 
on pathogen associated molecular patterns (PAMP), which are common 
components of many microorganisms and are not found in humans, i.e. 
lipopolisacharides (LPS). Ligation of PAMP with toll-like receptors (TLR) on the 
surface of APC (Bachmann and Kopf, 2002; Takeda et al., 2003) leads to 
phagocytosis and APP. APP results in the presentation of processed antigens to T 
cells (Cresswell and Lanzavecchia, 2001) (Fig.1) and the establishment of 
adaptive immunity (Kelly et al., 2002; Smyth et al., 2001).  
 
The function of adaptive immunity is the elimination of non-self antigens and the 
creation of immune memory. Constituents of adaptive immunity are B and T cells. 
Adaptive immunity is unique and created only after the encounter with a specific 
non-self antigen, which is presented to them by APC. Discrimination between self 
and non-self at the level of adaptive immunity is complex and involves the 
elimination or functional inactivation of self-reactive lymphocytes from the 
repertoire. Establishment of adaptive immunity is slow, but once it is established, 
it is memorized and able to respond faster to subsequent contacts with the same 
antigen. However, since innate immunity is faster, it keeps infections under 
control until the establishment of adaptive immunity (Smyth et al., 2003). 
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Very important role in APP, which connects innate and adaptive immunity, play 
the MHC determinants. Namely, processed antigenic peptides are presented to T 
cells only in the groove of MHC heterodimers. 
 
MAJOR HISTOCOMPATIBILLITY COMPLEX 
DETERMINANTS 
 
Genes that encode MHC determinants, also known as human leukocyte antigens 
(HLA), are located on the short arm of chromosome six and are extraordinary 
polymorphic (anonymous, 1999). They are divided into two classes; MHC I and 
MHC II determinants that present intracellular and extracellular antigens, 
respectively. MHC I determinants are expressed on most nucleated cells, whereas 
MHC II determinants only on APC, mature B and activated T cells.  
 
Three different MHC I determinants, namely HLA-A, HLA-B and HLA-C, are 
assembled and loaded with antigenic peptides, which are generated by protein 
degradation in the 26S proteasome, in the ER (Fruci et al., 2003; Saveanu et al., 
2002). The complex between MHC I heterodimer and antigenic peptide passes 
through the trans-Golgi network to the cell surface of APC and activates CD8+ T 
cells.  
 
In humans, there are three classical MHC II determinants termed HLA-DP, HLA-
DQ and HLA–DR, and two non-classical determinants named HLA-DM and 
HLA–DO (Fig. 2). The former are cell surface heterodimers that present antigenic 
peptides, whereas the latter are cytoplasmic oligomers that are involved in loading 
of antigenic peptides. HLA-DP, HLA-DQ, HLA–DR and HLA-DM are composed 
of α and β chains, whereas HLA-DO form heterotetramers, composed of two α 
and two β chains (Fig. 2). Classical MHC II determinants are assembled in the ER 
in the complex with the invariant chain (Ii), which stabilizes them and prevents 
premature loading of antigenic peptides. This complex is transported to the late 
endosome that contains degraded antigens. Loading of antigenic peptides is a 
three-step process (Fig. 2). The first two steps, which take place in the late 
endosome, are the degradation and immediate replacement of Ii by the class II-
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associated Ii-chain peptide (CLIP). The third step happens in the MHC class II 
compartment (MIIC) and is the exchange of CLIP with antigenic peptides. This 
exchange is mediated by HLA-DM and is regulated by HLA-DO. The complex 
between MHC II determinants and antigenic peptides then travels to the surface of 
APC, where the antigen is presented to CD4+ T cells, which are the main 
regulators of the immune response. 
 
Since they present antigens to CD4+ T cells, MHC II determinants are involved 
directly in the regulation of the immune response. Therefore, it is not surprising 
that the precise control of MHC II gene expression, which takes place at the level 
of transcription, is necessary for the equilibrated function of the immune system. 
Most of our knowledge about this control has been elucidated from studies of the 
severe combined immunodeficiency called MHC II deficiency or the type II bare 
lymphocyte syndrome (BLS) (Table 2).  
 
BARE LYMPHOCYTE SYNDROME 
  
BLS is an autosomal recessive disease characterized by the lack of constitutive 
and inducible MHC II gene expression (Table 2) (reviewd in (Reith and Mach, 
2001) and (Nekrep et al., 2003)). It is caused by mutations in factors that direct 
the transcription from MHC II promoters rather than in MHC II genes themselves. 
More than ten years ago, transcription of MHC II genes was known to require 
several unidentified proteins. The earliest studies performed to identify these 
proteins employed in vitro assays, which revealed many irrelevant DNA-protein 
interactions. However, only genetic studies of BLS finally resolved this puzzle. 
First, CIITA (Steimle et al., 1993) and regulatory factor X 5 (RFX5) (Steimle et 
al., 1995) were identified, which rescued the expression of MHC II determinants 
in complementation group (CG) A and C, respectively. Subsequently these 
findings led to the identification of regulatory factor X that contains ankyrin 
repeats (RFXANK/B) (Masternak et al., 1998; Nagarajan et al., 1999) and 
regulatory factor X associated protein (RFXAP) (Durand et al., 1997) that rescued 
the expression of MHC II determinants in CG B and D, respectively. These 
factors not only account for four CG of BLS, but also represent all gene-specific 
trans-acting factors that bind cis-acting elements for MHC II transcription.    
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cis-ACTING ELEMENTS 
 
MHC II genes are transcribed from compact promoters (Fig. 3A). They contain 
variable proximal promoter (PPS) and conserved upstream sequences (CUS) 
(reviewed in (Nekrep et al., 2003; Reith and Mach, 2001; Ting and Trowsdale, 
2002)).  
 
In HLA-DRA PPS are located from position – 52 to the transcription start site. 
From the 5’ direction, they contain octamer binding site (OBS) and initiator (Inr) 
sequences, but lack a functional TATA box. OBS binds the octamer binding 
protein-1 (Oct-1), which recruit the B cell octamer binding protein 1/Octamer 
binding factor 1/Oct coactivator from B cells (Bob1/OBF-1/OCAB) (Matthias, 
1998), whereas the initiator, which represents the transcription start site, binds 
RNA polymerase II associated transcription factor I (TFIII) and TATA binding 
protein (TBP) associated factor of 250 kDa (TAFII250).   
 
CUS are located from positions –139 to –67. From the 5’ direction, they contain 
S, X and Y boxes. X box can be further divided into X1 and X2 boxes. Tight 
spatial constraints are preserved between these boxes (Jabrane-Ferrat et al., 1996), 
which bind different trans-acting factors. S and X1 boxes bind RFX (Table 2) 
(Jabrane-Ferrat et al., 1996; Ting and Trowsdale, 2002), the X2 box binds X2 
binding protein (X2BP), which can be c-AMP responsive element binding protein 
(CREBP) or activator protein 1 (AP-1) (Moreno et al., 1997; Setterblad et al., 
1997) and the Y box binds nuclear factor Y (NF-Y) (Table 2) (Maity and de 
Crombrugghe, 1998; Mantovani, 1999).  
 
However, PPS and CUS are not sufficient for HLA-DRA gene expression. A 
distal locus control region (LCR), which is located approximately 2.4 kb upstream 
of the CUS, is needed for efficient transcription from the HLA-DRA promoter in 
the organism (Masternak et al., 2003) (Fig. 3). LCR is a mirror image of CUS. It 
contains S’, X1’, X2’ and Y’ boxes, but in the opposite orientation from the 
promoter. Indeed, the LCR binds the same trans-acting factors as the CUS.  
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trans-ACTING FACTORS  
 
Several trans-acting factors are required for MHC II transcription (Fig. 4). Among 
them, RFX and NF-Y create the platform for other co-activators to access MHC II 
promoters.     
 
NF-Y is composed of three subunits (Table 2) (reviewd in (Matuoka and Yu 
Chen, 1999)). NF-YA contains 374 residues. At the N-terminus of NF-YA, there 
is glutamine-rich region, which is followed by a stretch of prolines, serines and 
threonines. Its subunit interaction and DNA binding domains (DBD) are at the C-
terminus.  
 
NF-YB contains 207 residues. They form a histone fold and TATA-binding 
protein (TBP) binding domains. The histone fold is similar to that of histones 2A 
and 2B (Mantovani, 1999), which is responsible for their dimerization. This 
domain has the same function in the assembly of NF-Y. 
 
NF-YC contains 335 residues. As with NF-YB, it contains a histone fold and TBP 
binding domains, and in addition, a glutamine-rich region.  
 
RFX is also composed of three subunits (Table 2) (reviewd in (Reith and Mach, 
2001)). RFXANK/B contains 260 residues that form an acidic domain and four 
ankyrin repeats, which gave it its name.  
 
RFX5 contains 616 residues, which form DBD and PEST domains. It is the 5th 
member of the RFX family that binds S and X boxes of MHC II promoters, which 
gave it its name.  
 
RFXAP contains 272 residues. This protein has acidic, basic and glutamine-rich 
domains. Because it interacts directly with RFX5, it was named the RFX 
associated protein.  
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Transcription from MHC II promoters starts after productive interactions between 
cis-acting elements and trans-acting factors, which lead to the formation of the 
MHC II enhanceosome and transcriptosome. 
 
MHC II ENHANCEOSOME AND TRANSCRIPTOSOME 
 
The MHC II enhanceosome is formed on CUS and LCR. Its assembly requires 
specific protein-protein and DNA-protein interactions. The formation of the 
enhanceosome starts off DNA (Fig. 5) where RFX and NF-Y bind loosely. Both 
RFX and NF-Y are formed in two steps. RFXANK/B forms a complex with 
RFXAP, which binds the RFX5 oligomer (Jabrane-Ferrat et al., 2002). NF-YB 
and NF-YC first form heterodimer via their histone folds and then bind NF-YA. 
RFX and NF-Y are linked via interactions between RFXANK/B, NF-YA and NF-
YC (Jabrane-Ferrat et al., 2002; Nekrep et al., 2003; Ting and Trowsdale, 2002). 
The binding of the enhanceosome to promoters occurs via DBD of RFX5, NF-YB 
and NF-YC. Each individual contact between the enhanceosome and DNA takes 
place on the same side of the double helix. As mentioned earlier, preserved spatial 
constraints are present in CUS and LCR. Completely invariant spacing between S 
and X boxes can be explained by the RFX5 oligomers, which bind each others 
next to theirs DBD. These higher ordered RFX complexes can occupy S and X 
boxes only if the exact spacing between them is preserved. Between X and Y 
boxes are tolerated full helical turns. This finding can be explained because their 
binding occurs far from DBD.  
 
NF-Y not only interacts with RFX, but also with different histone 
acetyltransferases (HAT) that make chromatin accessible for other co-activators 
(Fontes et al., 1999; Harton et al., 2001).  Moreover, NF-YB and NF-YC bind 
TBP in vitro. This interaction helps to attract general transcription factors (GTF) 
to promoters, which lack a TATA box. The X2 box is bound by CREBP or AP-1 
(Moreno et al., 1995; Setterblad et al., 1997).  
 
The very last step is the recruitment of CIITA to the MHC II enhanceosome, 
which converts it into the MHC II transcriptosome (Fig. 5). Once the 
transcriptosome is formed MHC II genes can be transcribed.   
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CLASS II TRANSACTIVATOR 
 
CIITA is the master regulator of MHC II gene expression. Except for CIITA, all 
trans-acting factors that are needed for the transcription of MHC II genes are 
expressed ubiquitously. Thus, the synthesis of MHC II determinants correlates 
directly with the presence of CIITA, which is expressed constitutively only in DC 
and mature B cells and is inducible in most other cell types. After CIITA is 
recruited to the MHC II enhanceosome, it recruits the general transcriptional 
machinery. 
   
CIITA contains 1130 residues (Fig. 7). It can be divided into several domains, 
which are the N- terminal activation (AD), proline/serine/threonine rich (PST) and 
GTP binding domains (GBD), as well as the C-terminal leucine rich region 
(LRR). Additionally, CIITA contains three nuclear localization signals (NLS) and 
two putative nuclear export sequences (NES) (Fig. 7). 
 
The optimal AD of CIITA spans the first 322 residues. Its amino terminal part is 
rich in aspartic and glutamic acids and resembles the classical acidic AD, similar 
to that of VP16. Indeed, it can be replaced by AD from VP16 (herpes simplex) 
and E1a (adenovirus) (Riley and Boss, 1993). Between residues 145 and 322 is 
the PST domain. As its name implies, it contains several prolines, serines and 
threonines that are targets for post-translational modifications. A consensus PEST 
sequence is located from positions 283 to 308, but it does not represent a 
degradation motif or degron (Schnappauf et al., 2003). Rather, degrons are located 
within the first 99 residues and from positions 230 to 260 of CIITA, respectively 
(Schnappauf et al., 2003). 
 
A putative GBD resides downstream of AD, from positions 420 to 561. In 
contrast with the classical GBD, which contain four GTP-interacting sequences, 
CIITA contains only three (Harton et al., 1999). These are Walker type A motif 
(G1), magnesium coordination site (G3) and a site that confers specificity for 
guanosine (G4). Indeed, although CIITA binds GTP, it does not hydrolyse it in 
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vitro (Harton et al., 1999). This finding suggests that CIITA might be a 
constitutively active GTP-binding protein. As mutations of either motif reduce the 
activity of CIITA, the sole function of GTP binding to CIITA may be to alter its 
conformation.  
 
Five or six consensus LRR are located from positions 988 to 1097 (Harton et al., 
2002). They bind a 33 kDa protein of unknown function (Hake et al., 2000). 
Certain mutations positioned in α helices of LRR, but not in β sheets decrease the 
activity of CIITA. An additional LRR flanking the GBD might be involved in the 
aggregation of CIITA (Linhoff et al., 2001). 
 
In CIITA, three NLS and two NES have been described. A bipartite NLS is 
located from positions 141 to 159, and two additional NLS were mapped from 
positions 405 to 414 next to G1 and 940 to 963 in the LRR (Cressman et al., 1999; 
Cressman et al., 2001; Nekrep et al., 2002; Spilianakis et al., 2000). NES have 
been poorly characterized. The first is located in the first 114 residues, the second 
from positions 408 to 550 (Kretsovali et al., 2001). However, none of these NLS 
and NES have been examined directly.  
 
REGULATION OF CIITA GENE EXPRESSION 
 
Since the transcription of MHC II genes is dependent on the presence of CIITA, it 
is not surprising that its expression is highly regulated. In general, there are two 
types of regulation of gene expression: genetic and epigenetic. CIITA employs 
both. Whereas specific activators dictate active transcription, epigenetic silencing 
occurs via chromatin condensation. 
 
Transcription of CIITA can be initiated from up to three different promoters: PI, 
PIII and PIV (Fig. 6) (Muhlethaler-Mottet et al., 1997). In DC and mature B cells, 
constitutive expression of CIITA is initiated from PI and PIII, respectively 
(Muhlethaler-Mottet et al., 1997). IFN-γ inducible expression of CIITA is 
mediated by PI and PIV in bone marrow derived APC, DC and somatic cells, 
respectively (Muhlethaler-Mottet et al., 1997; Waldburger et al., 2001). All 
promoters have a unique exon 1, which is spliced into the common exon 2 
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(Muhlethaler-Mottet et al., 1997). Translation of CIITA transcripts from PI and 
PIII starts from the first methionine in exon 1, whereas from PIV it begins from 
the first methionine in exon 2. This brings unique sequences to the N-terminus of 
CIITA (Muhlethaler-Mottet et al., 1997) and results in three isoforms (IF) of 
CIITA: IF I, IF III and IF IV. IF I and IF III contain additional 94 and 17 residues, 
respectively. The additional sequence in IF I bears homology with the caspase 
recruitment domain (CARD) (Nickerson et al., 2001) and most likely represents a 
new protein-protein interaction domain. It also has the highest transcriptional 
activity (Nickerson et al., 2001). Importantly, a single mutation of a conserved 
leucine in CARD abrogates the activity of CIITA (Nickerson et al., 2001).  
 
Epigenetic regulation of CIITA gene expression is utilized for embryonic 
survival. Notably, immune responses against paternal antigens in the placenta 
cause fetal death. In these tissues, promoter hypermethylation and histone 
deacetylation are proposed mechanisms for silencing the transcription of CIITA 
(Holtz et al., 2003; Morris et al., 2000; van den Elsen et al., 2000). Derepression 
of CIITA transcription in trophoblasts after treatment with methylation inhibitors 
and trichostatin A with IFN-γ supports this mechanism.  
 
In immature DC, the expression of CIITA is observed from PI, but it does not lead 
to APP. Phagocytosis of an antigen leads to the maturation of DC, which is 
accompanied by the cessation of further phagocytosis and repression of de novo 
CIITA and MHC II transcription and up-regulation of APP (Cella et al., 1997; 
Landmann et al., 2001; Pierre et al., 1997; Turley et al., 2000). These events 
might be mediated by TLR. Because only the specific population of encountered 
antigens are processed and presented to T cells, such regulation could represent 
the best way of establishing adaptive immunity. Because the expression of CIITA 
is shut down after the clearance of a foreign antigen, it also lowers the chance of 
DC randomly presenting self-antigens.   
 
In B cells, the constitutive expression of CIITA from PIII is accompanied by the 
presence of high levels of MHC II determinants on the cell surface. However, 
after B cells differentiate into highly specialized antibody producing plasma cells, 
the expression of CIITA and MHC II determinants is lost (Chen et al., 2002). B 
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lymphocyte inhibitory maturation protein 1 (BLIMP1) begins the process of this 
silencing (Piskurich et al., 2000).  
 
CIITA gene expression can be induced with IFN-γ from PI and PIV. PIV contains 
gamma-activated sites (GAS), which bind the signal transducer and activator of 
transcription 1 (STAT1) and an interferon regulatory factor-1 binding site, which 
binds interferon regulatory factor-1 (IRF-1) (Muhlethaler-Mottet et al., 1998). 
Since PI is also responsive to IFN-γ, it could contain the same elements. After 
stimulation with IFN-γ, activated, phosphorylated STAT 1 translocates into the 
nucleus and binds GAS. Activated STAT 1 also induces the expression and 
accumulation of IRF-1. Binding of STAT 1 to GAS itself causes a weak 
acetylation of histones 3 and 4 in PIV (Morris et al., 2002). However, the 
hyperacetylation of histones, which makes transcription more efficient, happens 
only after the accumulation and binding of IRF-1 to its site.  
 
Thus, the regulation of transcription of the CIITA gene represents the first level of 
control of CIITA function. The second level consists of post-translational 
modifications of CIITA. 
 
POST-TRANSLATIONAL MODIFICATIONS OF CIITA   
 
CIITA is post-translationaly modified by acetylation, phosphorylation and 
ubiquitylation (Fig. 8). Effects of these modifications are complex and far from 
being clearly understood, but a general picture can be drawn from several studies. 
The fate of CIITA in the cell is not random, but each step, starting after its 
translation and ending with its possible degradation, is regulated precisely by the 
following modifications.     
  
Phosphorylation is the first post-translational modification of CIITA. Two studies 
have shown that this modification increases the activity of CIITA. The first study 
mapped phosphorylation sites into the PST region from positions 253 to 321 (Tosi 
et al., 2002). The second study showed that protein kinase A (PKA) 
phosphorylates CIITA on one or more serines in the region between PST and 
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GBD (Sisk et al., 2003). The phosphorylation of CIITA leads to its accumulation, 
oligomerization and nuclear translocation. Most likely, these latter events happen 
because the phosphorylation changes the conformation of CIITA and exposes its 
NLS. 
 
After it translocates into the nucleus, CIITA is acetylated on lysines 141 and 144, 
by CBP/p300 and also by pCAF, which are located in the nucleus (Spilianakis et 
al., 2000). Acetylation of these residues keeps CIITA in the nucleus and increases 
the stability of the MHC II transcriposome. Acetylation might also facilitate the 
subsequent ubiquitylation of CIITA. Indeed, recent data suggest that histone 
deacetylases (HDAC) are involved in the ubiquitylation of CIITA (Greer et al., 
2003).  
 
Ubiquitylation, which is a covalent modification of lysines, plays an important 
role in transcription. Monoubiquitylated transcription factors tend to be more 
potent activators, whereas polyubiquitylated proteins are destined for degradation 
by the 26S proteasome. The role of ubiquitylation of CIITA has been addressed in 
two studies, but clear conclusions on the function of ubiquitin cannot be reached. 
In the first study, monoubiquitin fused to CIITA prevented the degradation of the 
modified CIITA protein, but did not affect its transcriptional activity (Schnappauf 
et al., 2003). In the second study, CIITA co-expressed with ubiquitin had a higher 
activity than CIITA alone, which was even more pronounced if ubiquitin could 
not form oligomers (Greer et al., 2003). This effect of ubiquitin was on the 
stabilization of the MHC II transcriptosome rather than on transcription itself. 
Interestingly, the same study showed that HDAC prevent the ubiquitylation of 
CIITA.  
 
Phosphorylation also completes the post-translational modifications of CIITA. 
Interestingly, PKA inactivates CIITA with phosphorylation of serines 834 and 
1050. (Li et al., 2001). Does this modification influence the stability of the 
enhanceosome? Does it lead to the degradation of CIITA, or does it expose the 
NES and enables the export of CIITA from the nucleus?  
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CIITA IS SHUTTLING  PROTEIN 
 
Transcription factors and co-factors need to be transported into the nucleus to 
perform their function. Nucleo-cytoplasmic shuttling usually requires two types of 
functionally unique signals, NLS and NES. CIITA contains both, but none of 
them have been examined adequately (Fig. 7).  
 
At steady state, CIITA is distributed equally between the nucleus and the 
cytoplasm. Mutant CIITA proteins, which do not follow this pattern, led to the 
identification of NLS. As mentioned earlier, two NLS are located at the N-
terminus and one NLS in the C-terminus of CIITA (Fig. 7) (Cressman et al., 
1999), (Cressman et al., 2001), (Spilianakis et al., 2000). However, none of them 
has been examined directly, i.e. they have not been demonstrated to shuttle a 
heterologous protein. Moreover, binding to importins has not been investigated.  
 
Two regions in the N-terminus of CIITA have been proposed to function as NES 
(Fig. 7). The only support comes from interactions between these regions with the 
chromosomal region maintenance-1 (Crm-1) protein (Kretsovali et al., 2001). 
Indeed, treatment with leptomycin B (LMB), which blocks Crm-1 dependent 
nuclear export (Kudo et al., 1998), leads to the nuclear accumulation of CIITA 
(Cressman et al., 2001; Kretsovali et al., 2001). However, no consensus NES can 
be found within these sequences. In addition none of the five putative NES, three 
of which correspond perfectly to the consensus sequence [Lx(2,3)Lx(2,3)-LxL], 
functioned in a direct export nor bound Crm-1 (Drozina, Kohoutek, Peterlin, 
unpublished observation).  
 
All these results imply the presence of other transport mechanism/s. Indeed, 
several additional regions of CIITA are involved in its nuclear localization, 
including GBD (Harton et al., 1999; Raval et al., 2003) and LRR (Hake et al., 
2000; Harton et al., 2002; Towey and Kelly, 2002). Moreover, some mutations in 
the LRR disrupt interaction between p33 and CIITA, which interferes with its 
nuclear localization (Hake et al., 2000). Furthermore, it was suggested that NES 
from CIITA resemble that of snurportin-1, which is discontinuous (Paraskeva et 
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al., 1999). In this case, only after a conformational change can Crm-1 bind and 
transport snurportin-1 from the nucleus to the cytoplasm (Paraskeva et al., 1999). 
 
CIITA IS TRANSCRIPTIONAL  INTEGRATOR  
 
Once CIITA is modified appropriately and present in the nucleus, it can perform 
its function. It binds to the MHC II enhanceosome, attracts several transcription 
factors and co-factors and integrates initiation and elongation of transcription as 
well as chromatin remodeling into a process that finally results in the expression 
of MHC II genes. Moreover, CIITA might also be involved in the dissociation of 
the MHC II enhanceosome after the termination of transcription.  
 
CIITA recruits RNA polymerase II (RNAPII) to MHC II promoters and increases 
rates of initiation and elongation of transcription. For the former function, 
interactions with TAF (Fontes et al., 1997), TFIIB (Mahanta et al., 1997) and 
Bob1/OBF-1/OCAB (Fontes et al., 1996) might be necessary. For the latter, the 
interaction between CIITA and the positive transcription elongation factor b (P-
TEFb), which phosphorylates the CTD of RNAPII, is needed (Kanazawa et al., 
2000).    
 
Not surprisingly, CIITA also recruits HAT and chromatin remodeling machinery 
to the HLA-DRA promoter. The AD of CIITA binds CBP/p300 (Fontes et al., 
1999), pCAF (Spilianakis et al., 2000) and Brahma-related gene 1 (BRG-1) 
(Mudhasani and Fontes, 2002). In addition, it has been suggested that CIITA 
posseses intrinsic HAT activity (Harton et al., 2001; Raval et al., 2001). This 
activity of CIITA has been mapped into AD and bears homology with other HAT 
domains, e.g. in CBP/p300 (Harton et al., 2001). Interestingly, CIITA that lacks 
its AD is still able to mediate the acetylation of histone 4, but not of histone 3 
(Beresford and Boss, 2001). Thus, CIITA could contain another region with direct 
or indirect HAT activity.  
 
After the termination of transcription, deacetylation of histones, which is mediated 
by HDAC, is involved in chromatin condensation. Binding of CIITA to HDAC1 
and HDAC2 decreases the activity of CIITA, most probably because histone 
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deacetylation disrupts the MHC II enhanceosome (Zika et al., 2003). Thus, CIITA 
might play an active role in the regulation of its own function on MHC II 
promoters.  
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
In the last few years, much research resulted in greater understanding of the 
function and regulation of CIITA. Since CIITA plays a major role in the 
regulation of the immune response via MHC II determinants, this is not 
surprising. Moreover, if one understood the “rules” of this regulation, one could 
use this knowledge for the manipulation of the immune system. However, many 
questions remain. 
 
Why is CIITA transcribed from three distinct promoters? Are different IF of 
CIITA modified differently, which influences their activity and regulation?  
Are post-translational modifications independent from each other or are they 
carefully orchestrated or sequential? The phosphorylation of CIITA increases or 
decreases the activity of CIITA, depending on phosphorylated residues. What 
signals regulate this phosphorylation that results in activation and inactivation of 
CIITA, respectively, and how? Why does the acetylated CIITA protein 
accumulate in the nucleus? What is the role of its ubiquitylation? Where is CIITA 
ubiquitylated? These and probably many more questions regarding the post-
translational modifications of CIITA still need to be answered. 
 
The shuttling of CIITA is a big puzzle. Since CIITA has not been shown to bind 
importins and since no NES can be found, how does CIITA shuttle? And why 
does it shuttle at all?  
 
A lot is known about the cis-acting elements in the MHC II promoters, but the 
role of LCR needs more attention. What is the mode of action of these LCR? Do 
they also bring P-TEFb to RNAPII? How many LCR are there in the MHC 
cluster?  
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Once these questions have been answered, the manipulation of the immune 
system could become possible and eventually applicable in clinical medicine. 
Cancer and inadequate vaccination represent weak immune responses. 
Introduction of the constitutively active CIITA proteins could turn cancer cells 
into APC. They would then present their own antigenic peptides to CD4+ T cells 
to activate and direct immune response against transformed cells. Vaccination 
could also be more effective with the addition of CIITA. Autoimmunity is caused 
by the inappropriate responses to self-antigens. Dominant negative CIITA 
proteins could attenuate immune responses as well as the need for other 
immunosuppressive therapies. Thus, CIITA could become a new tool for 
immunotherapy in humans.  
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Table 1.  
 INNATE ADAPTIVE 
Tolerance to self 
Specificity 
Diversity 
Memory 
Cells 
Yes 
Low 
Low 
None 
APC 
Yes 
High 
High 
Yes 
B and T cells 
 
Abbrevation: APC; antigen presenting cells.  
 
Table 2.  
 
Complementation 
group 
A B C D 
MHC II expression 
Enhanceosome 
Mutated gene 
Mutated protein 
Absent 
Formed 
MHC2TA 
CIITA 
Absent 
Not formed 
RFXANK/B 
RFXANK/B 
Absent 
Not 
formed 
RFX5 
RFX5 
Absent 
Not formed
RFXAP 
RFXAP 
 
Abbrevations: MHC2TA; major histocompatibility class 2 trans-activator, 
RFXANK/B; regulatory factor X ANK/B, RFX5; regulatory factor X 5, RFXAP; 
regulatory factor X AP, CIITA; class II transactivator. 
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FIGURE LEGENDS 
 
Figure 1.  Pathway of antigen processing and presentation (APP) 
HLA-DP, HLA-DQ, HLA-DR, which are in complex with Ii, and HLA-DM heterodimers are 
assembled in the endoplasmic reticulum (ER, depicted in blue). They travel to the trans Golgi 
network (depicted in pink) and either fuse with the late endosome (depicted in orange) or continue 
to the cell surface. Degradation of phagocytozed antigenic peptides (depicted in violet) starts in an 
early endosome (depicted in green). In the late endosome, Ii is removed from the complex with 
HLA-DP, HLA-DQ, HLA-DR and replaced with antigenic peptides. Loaded with antigens, MHC 
II molecules travel from MHC class II compartment (MIIC, depicted in yellow) to the cell surface, 
where they activate T cells.   
 
Figure 2.  The organization and direction of MHC II genes, as well as sub-cellular 
localization of their proteins  
Three heterodimers are transcribed from promoters that point in opposite directions (HLA-DPA 
and HLA-DPB, HLA-DQA and HLA-DQB, HLA-DRA and HLA-DRB), HLA-DO heterodimer 
and HLA-DM heterotetramer are transcribed from promoters that point towards the telomere. 
Genes for α and β chains are shown as red and green bars, respectively. Pseudogenes and MHC II 
unrelated genes are shown as grey and yellow bars, respectively. Black arrows point in the 
direction of transcription.  
 
HLA-DP, HLA-DQ and HLA-DR heterodimers are found on the cell surface in complex with 
antigenic peptides. HLA-DM heterodimers and HLA-DO heterotetramers are cytoplasmic 
molecules, as well as invariant chain (Ii), all of which are also found in MHC class II 
compartments (MIIC, depicted as yellow circles). Genes coding for HLA-DP, HLA-DQ, HLA-
DR, HLA-DM and HLA-DO are located on the short arm of chromosome 6, but gene coding for Ii 
is located on the chromosome 5. 
 
Figure 3.  cis-acting elements in the DRA promoter 
Locus control region (LCR), conserved upstream sequences (CUS), and proximal promoter 
sequences (PPS) are needed for the transcription from the DRA promoter. LCR is located 2.4 kb 
upstream from CUS. LCR and CUS contain Y’, X2’, X1’, S’ and S, X1, X2 and Y boxes, 
respectively. PPS contain the octamer binding site (OBS) and the initiator (INR).  
The spacing between CUS and PPS are presented in the lower pannel.  
 
Figure 4.   cis-acting elements and trans-acting factors on MHC II promoters 
Conserved upstream sequences (CUS) contain S, X and Y boxes. X box is divided into X1 and X2 
boxes. In DRA gene, the octamer binding site (OBS) and the initiator (INR) form the proximal 
promoter sequences (PPS). RFX, which contains RFXANK, RFXAP and RFX5, binds S and X1 
boxes. X2 binding protein (X2BP) binds X2 box. NF-Y, which contains NF-YA, NF-YB and NF-
YC, binds Y box. OBS binds octamer binding protein-1 (Oct-1), which recruit the B cell octamer 
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binding protein 1/Octamer binding factor 1/Oct coactivator from B cells (Bob1/OBF-1/OCAB). 
The initiator binds general transcription factors and positions RNA polymerase II (RNAPII) on the 
promoter. CIITA is recruited to the MHC II enhanceosome, which consists of RFX, X2BP and 
NF-Y on CUS. It binds histone acetyl-transferases (HAT, CBP/p300, pCAF) and Brahma related 
gene (BRG) proteins that remodel the chromatin, Bob1/OBF-1/OCAB, GTF and TAF that recruit 
RNAPII and initiate transcription, and positive transcription elongation factor b (P-TEFb), that 
phosphorylates the C terminal domain (CTD) of RNAPII and facilitates the elongation of 
transcription. These steps in the transcriptional process are given above the drawing.     
 
Figure 5.  Assembly of the MHC II enhanceosome and transcriptosome 
RFXANK/B forms complex with RFXAP, which recruits the RFX5 oligomer. RFX binds S and 
X1 boxes, whereas NF-Y binds Y box. They form the MHC II enhanceosome. The 
phosphorylation of CIITA leads to its oligomerization and nuclear import. It binds to the MHC II 
enhanceosome and forms the MHC II transcriptosome, which forms the preinitiation complex 
(PIC) and recruits as well as modifies RNA polymerase II (RNAPII). 
 
Figure 6.  CIITA promoters, their composition and specificity  
CIITA is transcribed from three different promoters: PI, PIII and PIV with unique exons 1 
(depicted as red, purple, and green boxes for PI, PIII, and PIV, respectively) that are spliced into 
common exon 2 (depicted as a blue box). The additional sequences in CIITA, transcribed from PI 
is given in red letters and from PIII in purple letters, while a common sequence from all promoters 
is given in green letters. Cell types and stimuli are given above the scheme.  Abbreviations: IFN-γ, 
interferon gamma; APC, antigen-presenting cells; DC, dendritic cells.   
 
Figure 7.  The scheme of CIITA, its post-translational modifications and partner proteins 
CIITA is divided into several domains, which are activation (AD), proline/serine/threonine rich 
(PST), GTP binding (GBD) domains and leucine-rich repeats (LRR). Additionally, two nuclear 
localization signals (NLS) are located in the N-terminus and one in the C-terminus of the protein. 
Within PST domain there is a consensus proline/glutamine/serine/threonine rich (PEST) sequence. 
GBD contains three GTP interacting sequences, designated by G1, G3 and G4. Positions of post-
translational modifications of CIITA, which are phosphorylation, acetylation and ubiquitylation, 
are given above the drawing in red letters as PO4, Ac and Ub, respectively. Chromosomal region 
maintenence-1 protein (Crm-1, depicted as a purple box) interacts with AD and GBD, and p33 
(depicted as a white box) binds LRR. Transcriptional co-activators (TBP, TAFs, HATs, BRG-1, P-
TEFb) as well as constituents of the MHC II enhanceosome (RFXAP, RFX5, NF-YB, NF-YC and 
X2BP), which interact with CIITA, are listed under the drawing.   
 
Figure 8.  Post-translational modifications of CIITA   
After an unknown signal (depicted as the red arrow), CIITA is phosphorylated, which causes its 
oligomerization and nuclear translocation (black arrow directed from the cytoplasm into the 
nucleus). Acetylation and ubiquitylation increase transcriptional activity of CIITA. Termination of 
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transcription is accompanied by additional modifications of CIITA, possibly phosphorylation that 
might result in the translocation of CIITA into the cytoplasm (black arrow directed from the 
nucleus into the cytoplasm) or in its degradation. CIITA monomers and oligomers are depicted as 
gray and orange circles. Phosphorylation of CIITA is represented as a red P attached to CIITA. 
Acetylation and ubiquitylation of CIITA are depicted as red Ac and Ub, respectively. NLS and 
NES stand for nuclear localization signal and nuclear export sequence, respectively.      
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